Agios reports Q1 net loss $94.8M; PYRUKYND launch revenue $0.8M, cash $1.2B

AGIOS PHARMACEUTICALS, INC.

2022-Q1 EPS reported -$1.74 revenue$832,000

FDA approved PYRUKYND for PK deficiency in Feb 2022; U.S. launch generated $0.8M net revenue in partial quarter.
Net loss from continuing ops $94.8M vs $90.9M YoY; R&D spend $70.1M, SG&A $31.5M.
Cash & securities $1.2B (down from $2.4B YoY) due to $802.5M share repurchases in 2021; no need for equity.
Key 2022 milestones: EMA decision on PYRUKYND by year-end, start pediatric PK studies mid-2022.
Phase 2a study of AG-946 in MDS to initiate by year-end; AG-946 Phase 1 sickle cell cohort started.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.